Strategies to Reinvigorate Exhausted CD8 T Cells in Tumor Microenvironment

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jul 3

PMID 37398660

Authors

Qianting Guan

Meiwen Han

Qinghao Guo

Fangfei Yan

Ming Wang

Qin Ning

Dong Xi

Affiliations

Soon will be listed here.

Abstract

CD8 T cell exhaustion is a stable dysfunctional state driven by chronic antigen stimulation in the tumor microenvironment (TME). Differentiation of exhausted CD8 T cells (CD8 TEXs) is accompanied by extensive transcriptional, epigenetic and metabolic reprogramming. CD8 TEXs are mainly characterized by impaired proliferative and cytotoxic capacity as well as the increased expression of multiple co-inhibitory receptors. Preclinical tumor studies and clinical cohorts have demonstrated that T cell exhaustion is firmly associated with poor clinical outcomes in a variety of cancers. More importantly, CD8 TEXs are regarded as the main responder to immune checkpoint blockade (ICB). However, to date, a large number of cancer patients have failed to achieve durable responses after ICB. Therefore, improving CD8 TEXs may be a breakthrough point to reverse the current dilemma of cancer immunotherapy and eliminate cancers. Strategies to reinvigorate CD8 TEXs in TME mainly include ICB, transcription factor-based therapy, epigenetic therapy, metabolism-based therapy and cytokine therapy, which target on different aspects of exhaustion progression. Each of them has its advantages and application scope. In this review, we mainly focus on the major advances of current strategies to reinvigorate CD8 TEXs in TME. We summarize their efficacy and mechanisms, identify the promising monotherapy and combined therapy and propose suggestions to enhance the treatment efficacy to significantly boost anti-tumor immunity and achieve better clinical outcomes.

Citing Articles

Aging impairs CD8 T cell responses in adoptive T-cell therapy against solid tumors.

Kadyrzhanova G, Tamai M, Sarkar S, Kalra R, Ishikawa H Front Immunol. 2025; 16:1484303.

PMID: 39925817 PMC: 11803149. DOI: 10.3389/fimmu.2025.1484303.

Development of a prognostic model based on four genes related to exhausted CD8+ T cell in triple-negative breast cancer patients: a comprehensive analysis integrating scRNA-seq and bulk RNA-seq.

Shi Y, Yu Y, Zhao J, Huang L, Wang Q, Sun Q Discov Oncol. 2025; 16(1):114.

PMID: 39899181 PMC: 11790537. DOI: 10.1007/s12672-025-01812-z.

Myeloid cells meet CD8 T cell exhaustion in cancer: What, why and how.

Zhai Y, Liang X, Deng M Chin J Cancer Res. 2025; 36(6):616-651.

PMID: 39802897 PMC: 11724180. DOI: 10.21147/j.issn.1000-9604.2024.06.04.

Type I Interferon Drives a Cellular State Inert to TCR-Stimulation and Could Impede Effective T-Cell Differentiation in Cancer.

Corvino D, Batstone M, Hughes B, Kempchen T, Ng S, Salim N Eur J Immunol. 2024; 55(1):e202451371.

PMID: 39529512 PMC: 11739669. DOI: 10.1002/eji.202451371.

Effect of Nicotinamide Riboside Against the Exhaustion of CD8 T Cells via Alleviating Mitochondrial Dysfunction.

Xiao Y, Pang N, Ma S, Gao M, Yang L Nutrients. 2024; 16(21).

PMID: 39519411 PMC: 11547570. DOI: 10.3390/nu16213577.

References

Scott A, Dundar F, Zumbo P, Chandran S, Klebanoff C, Shakiba M . TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019; 571(7764):270-274. PMC: 7698992. DOI: 10.1038/s41586-019-1324-y. View

Guo Y, Xie Y, Gao M, Zhao Y, Franco F, Wenes M . Metabolic reprogramming of terminally exhausted CD8 T cells by IL-10 enhances anti-tumor immunity. Nat Immunol. 2021; 22(6):746-756. PMC: 7610876. DOI: 10.1038/s41590-021-00940-2. View

Miller B, Sen D, Al Abosy R, Bi K, Virkud Y, LaFleur M . Subsets of exhausted CD8 T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019; 20(3):326-336. PMC: 6673650. DOI: 10.1038/s41590-019-0312-6. View

Qin Y, Vasilatos S, Chen L, Wu H, Cao Z, Fu Y . Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene. 2018; 38(3):390-405. PMC: 6336685. DOI: 10.1038/s41388-018-0451-5. View

Seo H, Gonzalez-Avalos E, Zhang W, Ramchandani P, Yang C, Lio C . BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat Immunol. 2021; 22(8):983-995. PMC: 8319109. DOI: 10.1038/s41590-021-00964-8. View

Jansen C, Prokhnevska N, Master V, Sanda M, Carlisle J, Bilen M . An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019; 576(7787):465-470. PMC: 7108171. DOI: 10.1038/s41586-019-1836-5. View

Skokos D, Waite J, Haber L, Crawford A, Hermann A, Ullman E . A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. Sci Transl Med. 2020; 12(525). DOI: 10.1126/scitranslmed.aaw7888. View

Wu T, Madireddi S, de Almeida P, Banchereau R, Chen Y, Chitre A . Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature. 2020; 579(7798):274-278. DOI: 10.1038/s41586-020-2056-8. View

Liu C, Somasundaram A, Manne S, Gocher A, Szymczak-Workman A, Vignali K . Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. Nat Immunol. 2020; 21(9):1010-1021. PMC: 7442600. DOI: 10.1038/s41590-020-0733-2. View

10.

Chen J, Lopez-Moyado I, Seo H, Lio C, Hempleman L, Sekiya T . NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019; 567(7749):530-534. PMC: 6546093. DOI: 10.1038/s41586-019-0985-x. View

11.

Li Z, Tuong Z, Dean I, Willis C, Gaspal F, Fiancette R . In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue. J Exp Med. 2022; 219(6). PMC: 9048291. DOI: 10.1084/jem.20210749. View

12.

Kallies A, Zehn D, Utzschneider D . Precursor exhausted T cells: key to successful immunotherapy?. Nat Rev Immunol. 2019; 20(2):128-136. DOI: 10.1038/s41577-019-0223-7. View

13.

Chen W, Teo J, Yau S, Wong M, Lok C, Che C . Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8 T cell exhaustion and curtails anti-PD-1 efficacy. Cell Rep. 2022; 41(7):111647. DOI: 10.1016/j.celrep.2022.111647. View

14.

Seo H, Chen J, Gonzalez-Avalos E, Samaniego-Castruita D, Das A, Wang Y . TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8 T cell exhaustion. Proc Natl Acad Sci U S A. 2019; 116(25):12410-12415. PMC: 6589758. DOI: 10.1073/pnas.1905675116. View

15.

Yang R, Cheng S, Luo N, Gao R, Yu K, Kang B . Distinct epigenetic features of tumor-reactive CD8+ T cells in colorectal cancer patients revealed by genome-wide DNA methylation analysis. Genome Biol. 2020; 21(1):2. PMC: 6937914. DOI: 10.1186/s13059-019-1921-y. View

16.

Arenas-Ramirez N, Zou C, Popp S, Zingg D, Brannetti B, Wirth E . Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Sci Transl Med. 2016; 8(367):367ra166. DOI: 10.1126/scitranslmed.aag3187. View

17.

Ghoneim H, Fan Y, Moustaki A, Abdelsamed H, Dash P, Dogra P . De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell. 2017; 170(1):142-157.e19. PMC: 5568784. DOI: 10.1016/j.cell.2017.06.007. View

18.

Yost K, Satpathy A, Wells D, Qi Y, Wang C, Kageyama R . Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019; 25(8):1251-1259. PMC: 6689255. DOI: 10.1038/s41591-019-0522-3. View

19.

Hashimoto M, Araki K, Cardenas M, Li P, Jadhav R, Kissick H . PD-1 combination therapy with IL-2 modifies CD8 T cell exhaustion program. Nature. 2022; 610(7930):173-181. PMC: 9793890. DOI: 10.1038/s41586-022-05257-0. View

20.

Hanna B, Llao-Cid L, Iskar M, Roessner P, Klett L, Wong J . Interleukin-10 receptor signaling promotes the maintenance of a PD-1 TCF-1 CD8 T cell population that sustains anti-tumor immunity. Immunity. 2021; 54(12):2825-2841.e10. DOI: 10.1016/j.immuni.2021.11.004. View